Information Provided By:
Fly News Breaks for August 26, 2019
Aug 26, 2019 | 07:19 EDT
Credit Suisse analyst Matt Miksic reinstated coverage of Organogenesis (ORGO) with an Outperform rating and lowered his price target for the shares to $9 from $10. The company remains "very attractively valued," trading at a 50%-60% discount to other regen peers like Vericel (VCEL), AxoGen (AXGN) and MediWound (MDWD), Miksic tells investors in a research note. The analyst sees Organogenesis gaining share in the "high-value, high-growth" amniotic tissue segment of advanced wound care.
News For ORGO;VCEL;AXGN;MDWD From the Last 2 Days
Feb 25, 2020 | 07:58 EST
9th Annual Global Healthcare Conference will be held in New York on February 25-27.
Feb 25, 2020 | 07:12 EST
Reports Q4 revenue $5.4M, consensus $4.08M. "2019 was a transformational year for MediWound, and we have continued building on this momentum in what we believe will be a meaningful 2020," said Sharon Malka, Chief Executive Officer of MediWound. "We are very pleased to have our U.S. Phase 2 adaptive design study for EscharEx up and running. This study is designed to assess the efficacy and safety of our advanced once-a-day topical treatment in the debridement of venous leg ulcers. The study enables the comparison of EscharEx to placebo control, as well as a head-to-head comparison with the current non-surgical standard of care in the U.S. We believe EscharEx can be a game-changer, addressing a significant unmet medical need, and we anticipate having an interim assessment for this study by the end of the year. With regard to NexoBrid, we announced in early 2019 the results of the U.S. phase 3 DETECT study, which were robust across all endpoints, and subsequently reported the long-term follow-up safety data, which was comparable across all study arms. We are currently targeting the NexoBrid BLA submission for midyear 2020 and are actively preparing for commercial launch in the U.S. with our partner, Vericel. In addition, the NEXT program is up and running, allowing for the continued clinical use of NexoBrid for U.S. patients during the preparation and review of the NexoBrid BLA. Finally, the initiation of the NexoBrid procurement by BARDA prior to BLA submission is a significant milestone in our partnership with BARDA, which we believe will significantly increase U.S. readiness for burn mass casualty incidents. Our solid balance sheet and near-term cash inflows will continue to support our development plans and we look forward to several meaningful upcoming milestones in each of our programs."